Myovant Sciences’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Read more

Lynn Seely's photo - President & CEO of Myovant Sciences

President & CEO

Lynn Seely

CEO Approval Rating

89/100

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

ORILISSA is Myovant Sciences's top competitor. ORILISSA is a Product/Brand/Service company that was founded in North Chicago, Illinois in 2018. ORILISSA operates in the Pharmaceuticals industry. ORILISSA has 30 more employees vs. Myovant Sciences.

ObsEva has been one of Myovant Sciences's top competitors. ObsEva is headquartered in Plan-les-Ouates, Geneva, and was founded in 2012. ObsEva is in the Biotechnology field. ObsEva generates 28% the revenue of Myovant Sciences.

EndoCeutics is perceived as one of Myovant Sciences's biggest rivals. EndoCeutics was founded in 1957 in Quebec, Quebec. EndoCeutics competes in the Pharmaceuticals field. EndoCeutics generates $11.7M more revenue than Myovant Sciences.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ORIC a competitor of Myovant Sciences?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$33.3M

Myovant Sciences's revenue is the ranked 4th among it's top 10 competitors. The top 10 competitors average 61M. Over the last one quarters, Myovant Sciences's revenue has decreased by 0%. Specifically, in Q2 2020's revenue was $33.3M.

Acquisitions

No recent acquisitions found related to Myovant Sciences

Myovant Sciences Funding History

$218M$358M$758M$958M

Since Myovant Sciences was founded in 2016, it has participated in 5 rounds of funding. In total Myovant Sciences has raised $958.0M. Myovant Sciences' last funding round was on Aug 2020 for a total of $200.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Aug 2020
$200M
Debt
Oct 2019
$400M
Debt
Oct 2017
$100M

Novaquest Capital Management

Equity
Oct 2017
$40M

Novaquest Capital Management

IPO
Oct 2016
$218M
-

Total Funding: $958M

Since Myovant Sciences was founded in 2016, it has participated in 5 rounds of funding. In total Myovant Sciences has raised $958.0M. Myovant Sciences' last funding round was on Aug 2020 for a total of $200.0M

Investments

No recent investments found related to Myovant Sciences

Myovant Sciences News

August 19, 2020The Pharma Letter

FDA accepts NDA for relugolix combo for uterine fibroids

Switzerland-based Myovant Sciences (NYSE: MYOV) says that its New Drug Application (NDA) for once-dai... See more »
August 11, 2020NewsOk

Fiscal 1Q Earnings Snapshot

LONDON (AP) _ Myovant Sciences Ltd. (MYOV) on Tuesday reported a loss of $32.9 million in its fiscal ... See more »
August 5, 2020Benzinga

Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals

USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to furthe... See more »
July 7, 2020Zolmax News

Myovant Sciences (NYSE:MYOV) Price Target Raised to $29.00 at SVB Leerink

Myovant Sciences (NYSE:MYOV) had its price objective lifted by equities research analysts at SVB Leer... See more »
July 6, 2020MarketScreener

Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study

(marketscreener.com) Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes ... See more »

Myovant Sciences Press Releases

April 14, 2020centralcharts

Myovant Sciences and HealthyWomen Launch Storytelling Initiative to Elevate Conversations About Menstrual Health

Initiative to spotlight diverse, personal stories about menstruation in partnership with storytelling... See more »
March 10, 2020centralcharts

Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020

BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare co... See more »
February 10, 2020GlobeNewswire

Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

BASEL, Switzerland, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare com... See more »
October 31, 2019GlobeNewswire

Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders

BRISBANE, Calif. and BASEL, Switzerland, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MY... See more »
October 21, 2019GlobeNewswire

Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis

BRISBANE, Calif. and BASEL, Switzerland, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MY... See more »
August 7, 2019centralcharts

Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019

BASEL, Switzerland, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a clinical-stag... See more »
July 10, 2019GlobeNewswire

Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation

BASEL, Switzerland and SAN MATEO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: M... See more »

Headquarters

2000 Sierra Point Parkway 9th Floor

Brisbane, California94005

650-238-0250

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Myovant Sciences is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of fibroids and prostate cancer. Myovant Sciences was founded in 2016. Myovant Sciences' headquarters is located in Brisbane, California, U...

CEO

Myovant Sciences's President & CEO, Lynn Seely, currently has an approval rating of 89%. Myovant Sciences's primary competitors are ORILISSA, ObsEva & EndoCeutics.

Website

myovant.com

Frequently Asked Questions about Myovant Sciences

  1. When was Myovant Sciences founded?

    Myovant Sciences was founded in 2016
  2. Who is Myovant Sciences's CEO?

    Myovant Sciences's CEO is Lynn Seely
  3. How much revenue does Myovant Sciences generate?

    Myovant Sciences generates $33.3M in revenue
  4. How much funding does Myovant Sciences have?

    Myovant Sciences has historically raised $958M in funding
  1. Where is Myovant Sciences's headquarters?

    Myovant Sciences's headquarters is in Brisbane California, USA
  2. How many employees does Myovant Sciences have?

    Myovant Sciences has 20 employees
  3. What sector does Myovant Sciences operate in?

    Myovant Sciences is in Biotechnology, Pharmaceuticals
  4. Who are Myovant Sciences's competitors?

    Myovant Sciences's top competitors are ORILISSA, ObsEva, EndoCeutics